(Q40468950)

English

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.

scientific article published on 19 January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. (English)

1 reference

Europe PubMed Central

20 September 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

author name string

Lindsay M Hawkins

1

1 reference

Europe PubMed Central

20 September 2017

Aarthi A Jayanthan

2

1 reference

Europe PubMed Central

20 September 2017

Aru Narendran

3

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

19 January 2005

1 reference

Europe PubMed Central

20 September 2017

Pediatric Research

1 reference

Europe PubMed Central

20 September 2017

57

1 reference

Europe PubMed Central

20 September 2017

3

1 reference

Europe PubMed Central

20 September 2017

430-437

1 reference

Europe PubMed Central

20 September 2017

https://scigraph.springernature.com/pub.10.1203/01.pdr.0000153871.45184.19

0 references

Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Structural organization of the bcr gene and its role in the Ph' translocation

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Cellular signalling pathways: new targets in leukaemia therapy

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Overview: Translating Hsp90 Biology into Hsp90 Drugs

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Hsp90: chaperoning signal transduction

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Hsp90 & Co. - a holding for folding

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Mechanisms and implications of imatinib resistance mutations in BCR-ABL.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

STI-571: an anticancer protein-tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

BCR/ABL activates mdm2 mRNA translation via the La antigen

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Validating survivin as a cancer therapeutic target

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Regulation of survivin function by Hsp90

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Dysregulation of apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1203%2F01.PDR.0000153871.45184.19

21 January 2018

Identifiers

10.1203/01.PDR.0000153871.45184.19

1 reference

Europe PubMed Central

20 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40468950&oldid=1586500786"